<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58108</article-id><article-id pub-id-type="doi">10.7554/eLife.58108</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Sperm-specific COX6B2 enhances oxidative phosphorylation, proliferation, and survival in human lung adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-183179"><name><surname>Cheng</surname><given-names>Chun-Chun</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3657-8715</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-184854"><name><surname>Wooten</surname><given-names>Joshua</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-149326"><name><surname>Gibbs</surname><given-names>Zane A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0294-1878</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149328"><name><surname>McGlynn</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59985"><name><surname>Mishra</surname><given-names>Prashant</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-149038"><name><surname>Whitehurst</surname><given-names>Angelique W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9505-0240</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of Texas Southwestern Medical Center</institution>, <addr-line><named-content content-type="city">Dallas</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Project Management and Clinical Pharmacology</institution>, <institution>Nuventra</institution>, <addr-line><named-content content-type="city">Durham</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Children's Medical Center Research Institute</institution>, <institution>University of Texas Southwestern Medical Center</institution>, <addr-line><named-content content-type="city">Dallas</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-75453"><name><surname>Macleod</surname><given-names>Kay F</given-names></name><role>Reviewing editor</role><aff><institution>University of Chicago</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>angelique.whitehurst@utsouthwestern.edu</email> (AW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>09</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e58108</elocation-id><history><date date-type="received"><day>21</day><month>04</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Cheng et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Cheng et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58108-v1.pdf"/><abstract><p>Cancer testis antigens (CTAs) are proteins whose expression is normally restricted to the testis but anomalously activated in human cancer. In sperm, a number of CTAs support energy generation, however whether they contribute to tumor metabolism is not understood. We describe human COX6B2, a component of cytochrome c oxidase (complex IV). <italic>COX6B2</italic> is expressed in human lung adenocarcinoma (LUAD) and expression correlates with reduced survival time. COX6B2, but not its somatic isoform COX6B1, enhances activity of complex IV, increasing oxidative phosphorylation (OXPHOS) and NAD<sup>+</sup> generation. Consequently, COX6B2-expressing cancer cells display a proliferative advantage, particularly in low oxygen. Conversely, depletion of COX6B2 attenuates OXPHOS and collapses mitochondrial membrane potential leading to cell death or senescence. COX6B2 is both necessary and sufficient for growth of human tumor xenografts in mice. Our findings reveal a previously unappreciated, tumor specific metabolic pathway hijacked from one of the most ATP-intensive processes in the animal kingdom: sperm motility.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA196905</award-id><principal-award-recipient><name><surname>Cheng</surname><given-names>Chun-Chun</given-names></name><name><surname>McGlynn</surname><given-names>Kathleen</given-names></name><name><surname>Whitehurst</surname><given-names>Angelique W</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA142543</award-id><principal-award-recipient><name><surname>Cheng</surname><given-names>Chun-Chun</given-names></name><name><surname>Wooten</surname><given-names>Joshua</given-names></name><name><surname>McGlynn</surname><given-names>Kathleen</given-names></name><name><surname>Whitehurst</surname><given-names>Angelique W</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP180778</award-id><principal-award-recipient><name><surname>Mishra</surname><given-names>Prashant</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Joshua Wooten, Joshua Wooten is affiliated with Nuventra. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (2016-101795) at UTSW.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Sequencing data used was previously published by another group and is referenced.</p></sec><supplementary-material><ext-link xlink:href="elife-58108-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>